Measles virus causes immunogenic cell death in human melanoma

O G Donnelly1, F Errington-Mais, L Steele

  • 1Leeds Institute for Molecular Medicine, University of Leeds, Leeds, UK.

Gene Therapy
|December 16, 2011
PubMed

Insights

Measles virus (MV) effectively targets human melanoma, demonstrating its potential as an oncolytic virus (OV) therapy. This study shows MV enhances innate immunity and stimulates adaptive immune responses against melanoma.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses (OV) are emerging cancer therapeutics in clinical trials.
  • Measles virus (MV) has not been previously evaluated in human melanoma models.

Purpose of the Study:

  • To investigate the efficacy of MV against human melanoma.
  • To explore MV's role in modulating host antitumour immune responses.

Main Methods:

  • Utilized human in vitro models of melanoma.
  • Assessed MV-mediated melanoma cell death and its impact on immune responses.

Main Results:

  • Demonstrated MV's efficacy in targeting human melanoma cells.
  • Showcased MV-induced cell death as an inflammatory process, releasing cytokines and HMGB1.
  • Confirmed MV enhances innate antitumour activity.
  • Established that MV stimulates a melanoma-specific adaptive immune response.

Conclusions:

  • MV is a viable oncolytic virus for human melanoma treatment.
  • MV therapy can potentiate both innate and adaptive antitumour immunity.

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...